Tailoring Treatment

EHA 2016
Videos
Nikhil Munshi talks about modifying treatment to patients' expectations and what they can tolerate.

Related Items

Duration of TKI Treatment and Duration of Deep Molecular Response Affect Relapse-Free Survival in CML
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia
Finding Cost-Effective Ways to Good Outcomes
The European Hematology Association (EHA)
EHA 2016
Educating Caregivers and Looking at Patients' Quality of Life
The European Hematology Association (EHA)
EHA 2016
Understanding the Subsets of Lymphoma and Treating for Them
The European Hematology Association (EHA)
EHA 2016
Presidential Symposium: Friday, June 10
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia
ALL – Clinical Poster Session: Friday, June 10
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia
CLL – Clinical Poster Session: Friday, June 10
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia
ALL – Clinical Oral Presentations: Saturday, June 11
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia
5-Azacitidine plus Checkpoint Inhibitor May Enhance Outcomes in Patients with De Novo and Relapsed AML
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia
Venetoclax Is Safe and Effective When Combined with Rituximab in Relapsed CLL
The European Hematology Association (EHA)
EHA 2016, EHA 2016 – Leukemia

© Amplity Health. All Rights Reserved. Privacy Policy